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We have determined the number of circulating T, B and natural killer
cells in renal transplant recipients in order to detect changes during
cytomegalovirus (CMV) infections. Serial blood samples were taken
from 61 patients on standard triple immunosuppression therapy
(cyclosporin A, azathioprine and prednisone). Using two-color flow
cytometry analysis, the absolute number of CD3+, CD4+, CD8+,
CD19+, CD3+HLA-DR+ and CD16+56+ cells was determined. Forty-
eight patients (78.7%) developed active CMV infection, and all of
them subsequently recovered. Twenty of the infected patients (32.8%)
presented symptoms compatible with CMV disease during the infec-
tious process. The number of lymphocytes and their main subpopula-
tions were normal before the onset of CMV disease. During the
disease there was a decrease followed by a significant increase
(P<0.005) in the number of CD3+, CD4+, CD8+ and CD3+HLA-
DR+ cells. No significant changes were observed in natural killer cells
or B lymphocytes during the disease. We conclude, as observed in all
viremic patients recovering from infection, that recovery is associated
with an increase in the number of T cell subsets. The monitoring of
different lymphocyte subsets along with antigenemia can be extremely
useful in the detection of patients at high risk of developing CMV
symptoms, allowing the early introduction of antiviral therapy or the
reduction of immunosuppression therapy.
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Cytomegalovirus (CMV) is one of the
most important causes of infectious compli-
cations in organ transplant recipients (1,2). It
occurs in 43-92% of kidney transplant re-
cipients during the first months after trans-
plantation and is associated with a greater
net state of immunosuppression (3). In im-
munocompromised individuals it may be re-
activated from its latency and cause asymp-
tomatic or symptomatic infection, with se-
vere illness that may result in high mortality
(4,5). CMV infection can occur in both sero-
796
Braz J Med Biol Res 36(6) 2003
S.M. Castro et al.
positive and seronegative patients (6). The
incidence and intensity of the infection are
largely determined by the recipient’s pre-
transplant CMV serostatus, with seronega-
tive recipients of seropositive donors having
the highest risk for a serious primary infec-
tion. Reinfections may also be symptomatic
and severe, probably because of the fact that
a reinfection by a different strain of CMV
transmitted via the seropositive allograft is
also possible (7). In addition, antilympho-
cyte immunoglobulin (antithymocyte glo-
bulin, antilymphocyte globulin, OKT3 mono-
clonal antibodies), used either as induction
therapy or for allograft rejection treatment,
and the total dose of corticosteroids enhance
the rate of symptomatic CMV infection,
especially in CMV-seropositive individuals
(8).
The immune response against CMV is
complex and not fully understood. It is un-
able to eliminate the virus completely, al-
lowing it to persist in a latent state. The CMV
infection is known to cause changes in pe-
ripheral blood lymphocyte subpopulations.
A fast detection of CMV in peripheral blood
has been the goal of several studies in order
to correlate viremia and a clinical response.
However, while monitoring CMV disease,
we should also consider how much the im-
mune cell response is compromised.
Immunophenotyping has not been indi-
cated as relevant for the diagnosis of CMV
disease (9), but is considered important in
the elucidation of immune processes that
involve pre- and post-infection stages (9).
For this reason, immunological assays using
peripheral blood lymphocytes should be con-
sidered. Results obtained with murine mod-
els and observations on human material have
demonstrated the importance of T lympho-
cytes and natural killer (NK) cells in the
recovery from CMV infections (5,10).
In the present study we monitored lym-
phocyte subpopulations weekly, from pre-
transplantation to the 12th week post-trans-
plant, and correlated these results with CMV
disease events. We measured the subsets of
different lymphocyte populations, including
NK cells, in peripheral blood at weekly in-
tervals for 12 weeks post-renal transplanta-
tion, regardless of the presence or absence of
CMV disease. We examined only pheno-
typic changes in different cell populations,




Sixty-one consecutive adult renal trans-
plant recipients, with or without CMV infec-
tion, were studied prospectively. Baseline
immunosuppression consisted of a standard
triple drug regimen consisting of cyclosporin
A in combination with prednisone and aza-
thioprine. None of the patients had received
hyperimmune globulin or high-dose oral
acyclovir as prophylaxis against CMV. Trans-
plant rejections were documented by biopsy
and treated with methylprednisolone pulses;
steroid-resistant rejection was treated with
OKT3. In cases of symptomatic CMV infec-
tion, immunosuppression was reduced as a
first-line measure. Ganciclovir was given
when organs were involved or when CMV
disease was clinically judged to be severe.
The decision to initiate antiviral therapy was
made on a clinical basis, and on the basis of
the number of antigen-positive cells and with-
out prior knowledge of the lymphocyte acti-
vation status. The data of the patients studied
are summarized in Table 1.
Blood samples
The presence of CMV antigenemia in
peripheral blood and lymphocyte phenotyp-
ing were assessed in pre-transplant blood
samples from the recipients before the ad-
ministration of immunosuppressive drugs and
in post-transplant samples once a week until
the 12th week after transplantation.
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Table 1. Characteristics of renal transplant donors and recipients.
Recipient Sex Age Type of donor Immunosuppression Donor/recipient
(years) (Solumedrol, g) pre-transplantation serology
Date Type (ELISA)
1 M 39 01/11/96 C 3.0 +/+
2 M 37 01/11/96 C 3.0 +/+
3 M 68 01/21/96 C 0 ND/+
4 F 55 01/21/96 C 1.5 ND/+
5 M 43 01/30/96 C 2.5 ND/-
6 M 48 01/30/96 C 0 ND/+
7 F 65 02/06/96 R 0 +/+
8 M 39 02/13/96 R 3.5 +/+
9 F 23 02/22/96 C 3.0 ND/+
10 M 34 02/29/96 C 2.75 +/+
11 F 26 02/29/96 C 2.0 + OKT3 +/+
12 F 25 03/05/96 R 0 ND/+
13 F 26 03/13/96 C 0 ND/+
14 M 60 03/14/96 C 1.75 ND/+
15 F 28 04/02/96 R 3.0 +/+
16 F 67 04/13/96 C 2.25 +/+
17 F 33 04/14/96 C 1.875 +/+
18 M 46 04/17/96 C 3.75 ND/+
19 M 38 04/17/96 C 3.0 ND/+
20 M 53 04/22/96 C 2.25 +/+
21 F 25 04/22/96 C 3.75 +/+
22 M 28 05/07/96 R 1.75 -/+
23 M 37 05/09/96 R 4.75 +/+
24 F 34 05/21/96 R 3.5 + OKT3 +/+
25 M 64 05/28/96 R 3.75 +/+
26 M 41 06/10/96 C 6.0 ND/+
27 F 22 06/18/96 R 0 +/+
28 M 20 06/26/96 C 4.5 ND/-
29 M 21 07/12/96 C 4.0 +/-
30 F 57 07/12/96 C 2.25 +/+
31 F 28 07/18/96 R 0 +/+
32 F 19 07/23/96 R 0 +/+
33 M 46 07/29/96 C 2.25 +/+
34 M 45 07/30/96 R 3.75 +/+
35 F 24 08/13/96 R 0 +/+
36 M 23 08/28/96 C 1.5 +/+
37 F 40 08/28/96 C 1.5 +/+
38 M 55 09/10/96 R 0 +/+
39 F 15 09/17/96 R 1.5 +/+
40 F 36 09/23/96 C 3.0 +/+
41 M 60 09/26/96 C 3.75 -/+
42 M 42 10/01/96 R 0 +/+
43 M 54 10/12/96 C 1.5 +/-
44 F 18 10/13/96 C 0.75 +/-
45 M 48 10/15/96 R 0.75 +/+
46 F 27 10/18/96 C 4.75 +/+
47 F 56 10/18/96 C 0 +/+
48 F 43 10/29/96 R 0.75 +/+
49 F 19 11/11/96 C 0.75 ND/+
50 F 52 11/20/96 C 0 ND/+
51 M 55 11/20/96 C 2.0 ND/+
Continued on next page
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Virological methods
CMV antigenemia was determined as
described previously (11), using the Clonab
CMV - APAAP kit (Art. No. 812680, Biotest,
Dreilich, Germany). Briefly, peripheral blood
leukocytes were stained with immunoper-
oxidase using a mixture of monoclonal anti-
bodies C10 and C11, directed against the 65-
kDa CMV lower matrix phosphoprotein (12).
The number of antigen-positive cells per 105
polymorphonuclear leukocytes was counted
and designated as the viral load. IgG and
IgM antibodies against CMV were deter-
mined by ELISA.
Lymphocyte immunophenotyping
A whole-blood staining method was used
with the following monoclonal antibodies
(Becton Dickinson, San Jose, CA, USA):
anti-CD3-fluorescent isothiocyanate (T lym-
phocytes), anti-CD4-phycoerythrin (PE)
(TCD4 cells), anti-CD8-PE (TCD8 cells or
NK cells), anti-CD19-PE (B cells), anti-
CD16+56-PE (NK cells), and anti-HLA-DR-
PE (activated T, B or NK cells). A total of
2,500 cells in a lymphocyte gate were ana-
lyzed with an Ortho Cytoron Absolute Flow
Cytometer (Ortho Diagnostic Systems Inc.,
Raritan, NJ, USA). Absolute numbers of cells
were obtained using the same equipment.
Forty-one patients without clinical evi-
dence of CMV disease 3 months after trans-
plantation (at a time when all patients with
CMV infection had manifested subset
changes) served as controls.
Occurrence of CMV infection
Active CMV infection was defined by
the presence of antigenemia in peripheral
blood. Infection was considered to be pri-
mary when the patient was CMV seronega-
tive before transplantation and secondary in
the presence of pre-transplant IgG antibodies
against CMV (13).
Symptoms consistent with CMV disease
include fever, leukopenia, thrombocytope-
nia and/or elevation in serum transaminase
levels (14). The diagnostic criteria for symp-
tomatic CMV disease used in our study fol-
lowed the recommendations made by the
Workshop on Human CMV Disease (15).
Work-up for microorganisms other than
CMV included multiple bacteriological and
fungal cultures of blood, urine and sputum,
as well as serological tests and multiple chest
Recipient Sex Age Type of donor Immunosuppression Donor/recipient
(years) (Solumedrol, g) pre-transplantation serology
Date Type (ELISA)
52 M 37 11/26/96 R 0 +/+
53 M 49 12/04/96 C 2.25 +/+
54 F 31 12/05/96 C 0 +/+
55 M 29 12/08/96 C 3.25 ND/+
56 M 61 12/08/96 C 0.375 + OKT3 ND/+
57 M 16 12/10/96 R 2.875 + OKT3 +/+
58 M 44 12/14/96 C 0 ND/+
59 M 29 12/17/96 R 0 +/+
60 M 31 12/31/96 C 2.5 +/+
61 M 24 12/31/96 C 1.875 +/+
R: related donor, C: cadaver donor, OKT3: antilymphocyte T, (+): positive serology for CMV, (-): negative
serology for CMV, ND: not determined.
Table 1 continued.
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X-rays. CMV isolation was not attempted.
Informed consent was obtained from all pa-
tients and the protocol was approved by the
Hospital’s Ethics Committee.
Statistical analysis
Since the data were not distributed nor-
mally, the results are reported as medians.
Differences between two groups were com-
pared by the Mann-Whitney U-test. Differ-
ences at this level were then determined by
the minimum significant difference test after
K-W ANOVA (ZAR or Altam). The signifi-
cance level adopted was α = 0.05. All data
were processed and analyzed with the pro-
grams Epi-Info V4 and Statistical Package
for Social Sciences - SPSS V6.
Results
Sixty-one adult kidney graft recipients
transplanted at Santa Casa Hospital, Porto
Alegre, Brazil, were studied before trans-
plantation and for 12 weeks after transplan-
tation, from January to December 1996. Of
the 61 patients studied, 41 (67.2%) did not
show evidence of CMV disease in the first 3
months post-transplantation. Of these 41
patients, 28 (68.3%) presented active CMV
infection at some time during the study, while
the remaining 13 (31.7%) did not. Twenty
(32.8%) patients showed symptoms compat-
ible with mild or severe CMV disease at
some point during the 3-month study period.
The average time for the occurrence of CMV
infection was 6 weeks post-transplantation,
ranging from 4 to 11 weeks. Of the 20 pa-
tients with CMV disease, 8 (40.0%) had a
mild disease with leukopenia, fever and
thrombocytopenia, and 12 (60.0%) presented
severe CMV disease with fever and/or leu-
kopenia and/or pericarditis and/or thrombo-
cytopenia and/or hepatitis and/or gastroen-
teritis and/or rejection, requiring treatment
with ganciclovir. Of the 20 patients likely to
have CMV disease, 17 (85.0%) were posi-
tive for antigenemia before or during the
appearance of any clinical manifestation at-
tributable to CMV disease, and the other 3
were positive for antigenemia after the ap-
pearance of the clinical symptoms. All pa-
tients with symptomatic infection healed
spontaneously or after treatment with an an-
tiviral drug (Tables 2 and 3).
Immunophenotyping of lymphocyte
subpopulations
No cell population studied showed a sta-
tistically significant difference in its abso-
lute values before transplantation.
T lymphocytes (CD3+)
During the first week post-transplanta-
tion, no alteration occurred in the absolute
values of the total T lymphocyte population
compared to the pre-transplantation period
in either group (P = 0.3035). From week 2 to
week 12 post-transplantation, the group with
CMV disease showed lower T lymphocyte
levels than the group without CMV disease.
This difference between the two groups was
statistically significant from week 2 (P =
0.0121) through week 8 (P = 0.0204). In the
second month posttransplantation, the group
with disease showed the lowest T lympho-
Table 2. Pre-transplantation serology of donors and recipients and presence or ab-
sence of probable cytomegalovirus (CMV) disease during a period of 12 weeks post-
transplantation in the 61 adult renal transplant patients studied.
Pre-transplantation Without CMV disease With probable CMV disease
(IgG)
without active with active mild disease severe disease
infection infection
D-/R- 0 0 0 0
D-/R+ 1 0 0 1
D+/R- 0 0 0 3
D+/R+ 10 15 6 7
Donor ND/R+ 2 12 2 0
Donor ND/R- 0 1 0 1
Total 13 28 8 12
D: donor, R: recipient, ND: not determined.
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cyte levels, coinciding with the period of
greater incidence of the disease in our study.
From week 8 on, T lymphocyte values started
to increase in the group with disease, reaching
a peak at week 10 (P = 0.0302) and returning to
baseline at week 12 (P = 0.1150). Starting at
week 2 post-transplantation, the group with-
out CMV disease always presented 50% higher
T lymphocytes values (P = 0.000) compared to
the pre-transplantation period (Figure 1).
TCD4 cells (CD3+CD4+)
Prior to week 2 post-transplantation there
were no significant alterations in TCD4 cell
values in either group. From week 2 to week
12 post-transplantation, the group with CMV
disease showed significantly lower absolute
TCD4 cell values (P = 0.0003) than the
group without disease. Between week 5 and
7 the group with disease reached its mini-
mum TCD4 cell values, coinciding with the
period of greater disease incidence in our
study. From week 8 on, TCD4 cell number
started to increase in the group with CMV
disease, remaining significantly lower than
in the group without CMV disease until week
12 (Figure 2).
TCD8 cells (CD3+CD8+)
During week 1 post-transplantation there
was a decrease in the total count of TCD8
cells in both groups. From week 2 post-
transplantation on, the group with disease
showed still decreasing TCD8 cell values,
reaching minimum values at week 7. The
differences between the two groups were
statistically significant from week 2 to week
7 (P = 0.003). From week 8 on, TCD8 cell
values in the group with CMV disease started
to increase, reaching values close to baseline
at week 12. The group without CMV disease
had higher values than baseline from week 2
to the end of the 3-month post-transplanta-
tion period (Figure 3).
Table 3. Clinical manifestations, treatment and outcome of the graft of the 20 patients with probable cytomegalovirus (CMV) disease.
Patient Signs, symptoms and laboratory Post-transplantation time Classification Treatment Outcome
alterations at the beginning of clinical of CMV disease (ganciclovir)
manifestations (weeks) 10 mg kg-1 day-1 (days)
2 Fever, leukopenia, gastroenteritis 8 SD 24 Functioning
10 Fever, leukopenia 7 SD 21 Functioning
11 Fever, leukopenia, pericarditis 4 SD 21 Functioning
16 Leukopenia, thrombocytopenia 2 MD Not treated Functioning
17 Leukopenia, colitis 9 MD Not treated Functioning
20 Fever, leukopenia, thrombocytopenia 4 SD 14 Functioning
22 Fever, blister injuries on skin 7 SD 14 Functioning
24 Fever, leukopenia 4 SD 14 Functioning
25 Leukopenia 6 MD Not treated Functioning
28 Fever, leukopenia, epigastric pain 4 SD 14 Functioning
29 Fever, leukopenia, gastritis 7 SD 14 Functioning
30 Leukopenia 8 MD Not treated Functioning
40 Leukopenia 11 SD Not treated Functioning
43 Leukopenia, hepatitis 7 SD 14 Functioning
44 Fever, leukopenia, myalgia 4 SD 14 Functioning
46 Fever, leukopenia 5 SD 21 Functioning
47 Leukopenia 6 SD Not treated Functioning
53 Leukopenia 4 MD Not treated Functioning
56 Leukopenia 5 MD Not treated Functioning
58 Fever, leukopenia 5 MD Not treated Functioning
SD: severe disease, MD: mild disease.
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B lymphocytes (CD19+)
During the first and second week post-
transplantation an increase in the total num-
ber of B lymphocytes was observed both in
the group without CMV and in the group
with CMV disease. From the third week
there was a decrease in B lymphocyte values
in both groups. In the group without the
disease, values remained higher than base-
line during the 3-month study period, and in
the group with disease, values remained lower
than baseline from week 3 to week 12 post-
transplantation. There were significant dif-
ferences in B lymphocyte number between
groups at week 4 and 7 (P = 0.0076) (data not
shown).
Activated T lymphocytes (CD3+HLA-DR+)
In the group with CMV disease the num-
bers of activated T lymphocytes tended to
decrease from week 1 to week 7 post-trans-
plantation. From week 8, values increased,
reaching the levels of the pre-transplantation
period at week 12. The group without the
disease continued to show values close to
baseline throughout the 3 months of the
study. At week 6 post-transplantation, both
groups showed statistically significant dif-
ferences in total activated T lymphocyte val-
ues (P = 0.0422) (Figure 4).
NK cells (CD3-CD(16+56)+)
NK cell numbers were reduced by about
50% of their baseline values at week 1 post-
transplantation, remaining low until week
12 in both groups. At week 7 the levels of
NK cells decreased significantly in the group
with CMV disease (P = 0.0155) (data not
shown).
Discussion
Cytomegalovirus is one of the most im-
Figure 3. TCD8 cell concentra-
tion in blood among renal trans-
plant patients with and without
probable CMV disease. Data are
reported as medians ± interquar-
tile range for 61 patients.
*P<0.05 compared to CMV-posi-


















































Figure 2. TCD4 cell concentra-
tion in blood among renal trans-
plant patients with and without
probable CMV disease. Data are
reported as medians ± interquar-
tile range for 61 patients.
*P<0.05 compared to CMV-posi-



























Figure 1. T (CD3+) lymphocyte
concentration in blood among
renal transplant patients with
and without probable CMV dis-
ease. Data are reported as medi-
ans ± interquartile range for 61
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portant infectious agents that attack trans-
plant patients and is responsible for the sig-
nificant morbidity and mortality presented
by organ recipients (2,16).
Since antigenemia started to be used as a
quantitative marker of viral load, more ex-
tensive studies on the interaction between
CMV and host immune response have be-
come possible. This is a rapid, sensitive and
specific technique (17-19). The early detec-
tion of viral antigens in peripheral blood
leukocytes even before the disease is clini-
cally apparent (12), seems to be more appro-
priate to guide the beginning of early treat-
ment than viral culture, and can also permit
the monitoring of these cells during infec-
tion (2,9). Our findings are consistent with
previous studies showing that antigenemia is
a suitable method for the diagnosis of active
CMV infection and acts as an early marker
for active CMV infection in most patients.
No antigenemia-negative patient developed
CMV disease over the 3-month study period
(18,20), and of the 20 patients assumed to
have CMV disease, 17 presented positive
antigenemia prior to the appearance of clini-
cal symptoms.
Of the 41 patients who did not show any
signs of the disease at 3 months post-trans-
plantation, 28 were positive for antigenemia
at some point in the study, a fact supporting
previous studies showing that CMV vire-
mia/antigenemia may occur in asymptomat-
ic patients (4,21,22).
The mean time for the occurrence of
CMV disease was 6 weeks post-transplanta-
tion, which confirms the first 3 months post-
transplantation as the period of highest risk
to contract CMV disease (22-24).
Several groups have demonstrated that
the absence of cellular immunity in organ
recipients is an important factor for the de-
velopment of CMV disease (5,24-26). The
hypothesis that the immune cell response
can be monitored in vivo through immuno-
phenotyping by flow cytometry is of great
practical interest. The reproducibility of this
method permits serial sample analysis, as
performed in the present study. In addition,
the techniques for measuring the activity of
cytotoxic T lymphocytes or NK cells are
more expensive and laborious and require
greater time and space to carry out.
The absolute number of the cells studied
did not differ between the groups with and
without CMV disease before transplanta-
tion. Therefore, there was no difference in




























Figure 4. Activated T lympho-
cyte concentration in blood
among renal transplant patients
with and without probable CMV
disease. Data are reported as
medians ± interquartile range for
61 patients. *P<0.05 compared
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Figure 5. Total lymphocytes (CD3+) and the prevalence of CMV disease. The white columns
indicate the absolute number of lymphocytes/µl blood in the group of patients without CMV
disease (N = 40). The black columns indicate this same number in the group with CMV
disease (N = 21) and the gray columns indicate the incidence of CMV disease among our
patients (N = 61). The decrease in lymphocyte numbers precedes CMV disease. Data are
reported as medians ± interquartile range.
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the prediction of behavior during the post-
transplantation period, such as a tendency to
contract or to resist CMV disease.
Between week 2 and 7 the absolute num-
ber of total T lymphocytes, TCD4 cells and
TCD8 cells in the group with CMV showed
a pronounced decrease, significantly differ-
ing from the group without disease. This
period coincides with the mean period of
CMV disease occurrence, characterized by a
decrease in the cell response before the clini-
cal event, with later onset of CMV disease.
This pronounced reduction in the cell re-
sponse seems to involve an association be-
tween the immune system and CMV disease
(Figure 5).
After week 7, a rise in the absolute values
of total T lymphocytes occurred, with TCD8
cells showing the most significant increase.
This increase in TCD8 cells may represent
an effector path of activation involved in the
process of recovery from CMV disease or
may be nonspecific reflecting the activation
of the immune system.
Since all patients recovered from CMV
disease, our study agrees with the literature
suggesting that TCD8 cells participate in the
recovery from CMV infection (24,25,27,28).
Since most patients presented infection
through reactivation of the latent virus or
through the acquisition of exogenous strains
from transplanted organs, the TCD8 cell
response does not seem to be correlated with
suppression of the infection but it could be a
protection against severe CMV disease (25).
These effector cells seem to be involved in
the control of the infection by limiting the
systemic viral load.
While the role of TCD8 cells in the re-
covery from CMV has been shown to be of
capital importance, the participation of TCD4
cells still seems to be controversial. Our
results, as well as those of Rager-Zisman et
al. (29), suggest that both T cell subpopula-
tions participate in the protection against
fatal CMV disease. In the absence of TCD8
cells, TCD4 cells achieve a compensatory
protective activity which is absent in normal
mice recovering from viral infection and
TCD4 cells are believed to be instrumental
in the initiation of TCD8 cell expansion via
the stimulation of dendritic cells (30-32), but
their role in maintaining adequate numbers
and function of specific TCD8 cells is less
well understood.
TCD8 and NK cells appear to play a
complementary role in the recovery from
CMV infection. The recovery from the dis-
ease coincides with the expansion and acti-
vation of TCD8 and NK cells. In a primary
infection, both subpopulations act, while in
secondary infections only TCD8 cells are
supposed to be involved in the process. The
activation of TCD8 cells was associated with
the recovery from both primary and second-
ary infections and with the low risk of re-
lapse following antiviral therapy. NK cells
mainly respond upon primary infection and
seem to be less important in the recovery
from secondary infection or in CMV rein-
fection (33). A nonspecific cell response
may limit viral replication and the spread of
the disease at the early stage or upon primary
infection, while a specific cell response would
be necessary to control and keep the virus
latent. In a secondary infection, this specific
response could be more quickly activated,
and NK cells would play a minor role.
We did not detect a significant quantita-
tive alteration of NK cells in either group
studied, probably due to the small number of
primary infection cases, with the exception
of week 7, when there was a significant
decrease in the absolute number of NK cells
in the group with CMV disease, not detected
in the group without disease. The recovery
period was not followed by a significant
increase in NK cells.
Our results showed an increase in the
absolute number of T lymphocytes that ex-
press the activating antigen HLA-DR during
CMV disease. This increase occurred de-
spite the presence of cyclosporine, a drug
known to act as an inhibitor of antigen HLA-
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DR expression in lymphocytes (34,35). This
suggests that the activation of T cells by
virus induction is not inhibited by this drug.
Although changes in these cell subsets
do not provide a definitive diagnosis of CMV
disease, the consistency of the patterns de-
scribed will provide diagnostic support for
the suspicion of CMV disease, allowing the
patient to be better monitored.
Our results have important clinical impli-
cations, possibly establishing a “risk group”
for the development of CMV disease. Thus,
the monitoring of different lymphocyte sub-
sets along with antigenemia can be extremely
useful in the detection of patients at high risk
of developing CMV symptoms, allowing the
early introduction of antiviral therapy or the
reduction of immunosuppression therapy.
Even though further studies are needed, es-
pecially to verify the involvement of other
cell populations, our results are relevant and
of interest for later studies on the involve-
ment of the human immune system in CMV
disease.
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